ObsEva

    ObsEva [NASDAQ: OBSV; SIX: OBSN] is a Swiss-based, specialty biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labor. ObsEva was founded in 2012 by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a clinician specialized in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. He was previously Co-Founder and CEO of PregLem. André Chollet is a medicinal and pharmaceutical chemist with over 30 years of experience gained in diverse roles within the biopharmaceutical industry, including at Biogen, GSK and Merck Serono.

    SofinnovaCapital

    The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

    SofinnovaMD Start

    The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

    SofinnovaCrossover

    The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

    SofinnovaIndustrial Biotech

    Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

    SofinnovaTelethon

    The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

    Welcome to our new website – a fresh look that represents a new SofinnovaFind out more